Research Article

Investigation of the Vitamin D Receptor Polymorphisms in Acromegaly Patients

Muzaffer Ilhan,1 Bahar Toptas-Hekimoglu,2 Ilhan Yaylim,2 Seda Turgut,3 Saine Turan,2 Ozcan Karaman,1 and Ertugrul Tasan1

1Department of Endocrinology and Metabolism, Bezmialem University, 34093 Istanbul, Turkey
2Department of Molecular Medicine, The Institute of Experimental Medicine, 34093 Istanbul, Turkey
3Department of Internal Medicine, Bezmialem University, 34093 Istanbul, Turkey

Correspondence should be addressed to Ilhan Yaylim; ilhanyaylim@gmail.com

Received 13 October 2014; Revised 15 December 2014; Accepted 15 February 2015

Academic Editor: Dharambir K. Sanghera

Copyright © 2015 Muzaffer Ilhan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The genetic structural alterations in the majority of somatotroph adenomas are not clarified and the search for novel candidate genes is still a challenge. We aimed to investigate possible associations between vitamin D receptor (VDR) polymorphisms and acromegaly. Design, Patients, and Methods. 52 acromegaly patients (mean age 45.7 ± 1.9 years) and 83 controls (mean age 43.1 ± 2.6 years) were recruited to the study. VDR polymorphism was determined by polymerase chain reaction-based restriction fragment length polymorphism methods. Results. The distribution of VDR genotypes showed a significant difference in the frequencies of VDR FokI genotypes between patients and controls (P = 0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (P = 0.035) and carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly (OR: 1.5, 95% CI: 1.07–2.1; P = 0.020). IGF1 levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype (P = 0.0049). 25(OH)D3 levels were significantly lower in acromegaly patients (P < 0.001).

Conclusions. Our study suggests that VDR FokI genotypes might affect the development of acromegaly and VDR polymorphisms may play a role in the course of acromegaly as a consequence of altering hormonal status.

1. Introduction

Acromegaly is a rare disease characterized with elevated levels of growth hormone (GH) and insulin like growth factor 1 (IGF1) [1]. Acromegaly disease is almost always caused by pituitary GH overexpressing adenomas [2]. A few germline mutations have been shown to convey an inherited risk of somatotroph adenomas; however, the vast majority of these tumors are sporadic origin [3]. To date, the most frequent somatic molecular alterations identified are activating mutations in the guanine nucleotide-binding a-subunit 1 gene (GNAS) [4]. These mutations induce adenylyl cyclase activation, cellular proliferation, and GH oversecretion. However, no Gs alpha subunit (Gxs) mutations have been found in about two-thirds of sporadic acromegaly tumors indicating that there are other unknown mechanisms. Other molecular alterations have been reported, such as cAMP response element-binding protein (CREB) activation and pituitary tumor-transforming gene (PTTG) overexpression [5, 6]; however, the genetic structural alterations in the majority of sporadic somatotroph adenomas remain unknown and the seeking for novel candidate genes is still a challenge.

Beyond calcium homeostasis, vitamin D is a well-known potent regulator of cell growth and differentiation [7]. 1,25-Dihydroxyvitamin D3 [1,25(OH)2D3, calcitriol] binds to a corresponding intranuclear receptor and interacts with various cell cycle regulators identified in numerous genes involved in cellular growth, differentiation, apoptosis, and invasion by tumor cells such as the human p21/WAF1, cyclin A and cyclin E, human c-fos and c-myc, and the human retinoblastoma gene [8]. The vitamin D receptor (VDR) is encoded by a large gene located on chromosome 12q13-14 and forms a heterodimer with retinoid X receptors (RXRs) and both VDR and RXRs are the members of the steroid
nuclear receptor superfamily [9]. RXRs binding is essential for transcriptional activation of VDR [10]. While the function of the RXRs in tumorigenesis has not been studied as thoroughly as that of VDR, RXRs have been implicated in the tumorigenesis of somatotroph adenomas [11].

There are more than 470 single nucleotide polymorphisms (SNPs) identified in the VDR gene and locations of the polymorphisms determine their functional roles [12, 13]. The polymorphisms most extensively focused on are rs10735810 or FokI in exon 2, rs1544410 or BsmI in intron 8, rs731236 or TaqI in exon 9, rs7975232 or Apal in intron 8, rs757343 or Tru91 in intron 8, and the poly(A) mononucleotide repeat in the 3' UTR [12]. TaqI and Apal polymorphisms are considered to be silent nucleotide polymorphisms. However, the VDR FokI polymorphism leads to T>C substitution (T≡F, C≡f allele), resulting in a less potent transcriptional activator product [14]. On the other hand, the F allele leads to higher transcriptional and functional activities [13].

In the present study we aimed to investigate possible associations of vitamin D receptor polymorphisms and VDR activity levels with acromegaly and acromegaly disease characteristics.

2. Material and Methods

2.1. Patients and Hormone Assays. 52 acromegaly patients (31 females and 21 males) and 83 healthy controls (53 females and 30 males) were recruited to the study between 2011 and 2013 in Bezmialem University Hospital Endocrinology Clinic, Turkey. Our patients and controls were selected from the Turkish population. The diagnosis of acromegaly disease was based on clinical features and was confirmed by GH levels >0.4 ng/mL after an oral glucose tolerance test or high age-matched IGF1 levels [15]. Magnetic resonance imaging (MRI) of the hypophysis was performed on all acromegalic patients and maximum diameter was determined as the tumor size. Acromegaly disease is considered to be in biochemically remission, if nadir GH < 0.4 ng/mL during an OGTT or under random GH < 1 ng/mL for patients receiving medical treatment and normal age matched IGF1 levels [15]. IGF1 values were adjusted as IGF1/upper limit of normal range (ULN) * 100.

Blood GH and IGF1 levels were assayed using a chemiluminescence immunometric assay (Siemens Advia-Centaur USA). Age-related reference ranges for IGF1 were as follows: 18–20 y: 197–956; 20–23 y: 215–628; 23–25 y: 169–591; 25–30 y: 119–476; 30–40 y: 100–494; 40–50 y: 101–303; >50 y: 78–258 (ng/mL).

For the measurement of 25-hydroxyvitamin D3 [25(OH)D3] levels, blood was collected in polystyrene tubes and centrifuged immediately. The serum was stored at −30°C until 25(OH)D3 levels were determined by enzyme-linked immunoassay (Catalog number K2110; Immundiagnostik AG, Stubenwald-Alee 8a, D64625 Bensheim Austria). Reference range for 25(OH)D3 was 6.4–24 nmol/L.

This study was approved by the local ethics committee of Bezmialem Vakif University and informed consent was obtained in all cases.

2.2. VDR Genotyping Methods. Blood specimens were collected in tubes containing EDTA, and DNA samples were extracted from whole blood by a salting out procedure [16]. Genotyping was performed by the polymerase chain reaction (PCR) and restriction fragment length polymorphism (RF LP). For VDR gene TaqI and Apal polymorphisms, sense primer was 5'-AG AGC AGT AGC AGG GAG CAA G-3' and antisense primer was 5'-GCA ACT CCT CAT GGG C TG AGG TCT CA-3' [17]. For detection of the TaqI and Apal RF LP, 50–100 ng genomic DNA was amplified with 1X polymerase chain reaction buffer, 3 mM MgCl2, 0.2 mM of each dNTP, 0.2 mM of each primer, and Taq polymerase in a 50 µL reaction volume. Samples were denatured at 94°C and passed through 5 cycles of 94°C for 45 sec, 64°C for 60 sec, and 72°C for 2 min and a further 25 cycles of 94°C for 30 sec, 64°C for 30 sec, and 72°C for 45 sec. PCR products were digested with TaqI and Apal restriction enzyme at 65°C and 37°C. TaqI polymorphism genotypes were determined as TT (490 and 245 bp), Tt (490, 290, 245, and 205 bp), or tt (290, 245, and 205 bp) [17] and Apal polymorphism genotypes were determined as AA (740 bp), Aa (740, 530, and 210 bp), or aa (530 and 210 bp) [18]. The primers (MBI Fermentas, Lithuania) for FokI polymorphism were 5'-GAT GCC AGC TGG CCC TGG CAC TG-3' and 5'-ATG GAA ACA CCT TGC TTC TTC TCC-3'. The DNA template was amplified by PCR using 3 mM MgCl2. 0.2 mM of each dNTP, 0.25 mM of each primer, and Taq polymerase (MBI Fermentas, Lithuania) in a 50 µL final volume. The PCR conditions involved an initial denaturation of 4 min at 94°C, followed by 30 cycles of 94°C for 1 min, annealing at 66°C for 1 min, and extension at 72°C for 1 min. A final extension step at 72°C for 4 min was also studied. PCR products were digested with FokI restriction enzyme (MBI Fermentas, Lithuania) at 37°C for 3 h followed by electrophoresis in a 2% agarose gel. The FF genotype (homozygote of common allele) shows only one band of 272 bp in agarose gel. The ff genotype (homozygote of infrequent allele) generates two fragments of 198 and 74 bp. The heterozygote displays three fragments (272, 198, and 74 bp) [17].

2.3. Statistical Analysis. Differences in the frequencies of the VDR polymorphisms between acromegaly patients and the control group were analyzed using the Chi-square test. Hardy Weinberg equilibrium (HWE) was tested for all polymorphisms. The associations in means between groups were analyzed by Student's t-test or ANOVA and Mann-Whitney U or Kruskal-Wallis tests depending on data distribution. Spearman's coefficient was applied to test for bivariate correlations. The relative associations between acromegaly patients and controls were assessed by calculating crude Gart's odds ratios (ORs) and 95% confidence intervals (95% CIs). The threshold for significance was \( P < 0.05 \). The SPSS version 11.0 for Windows was used to perform statistical analysis (SPSS Inc. Chicago, IL, USA). Haplotype frequencies, \( D^2 \) (a normalized measure of linkage disequilibrium between the two loci), and \( r^2 \) (the correlation coefficient between the two loci) were calculated using Haplovieview software version 4.2 [19].
### Table 1: Demographic characteristics of acromegaly patients and control group.

|                      | Acromegaly (n = 52) | Control (n = 83) |
|----------------------|---------------------|-----------------|
| Gender (n, %)        |                     |                 |
| Female               | 31 (59.6)           | 53 (63.9)       |
| Male                 | 21 (40.4)           | 30 (36.1)       |
| Age (y)              | 45.7 ± 1.9          | 43.1 ± 2.6      |
| Age onset (y)        | 45.7 ± 1.9          | 43.1 ± 2.6      |
| Tumor size before treatment (n, %) |         |                 |
| Macroadenoma         | 36 (81.8)           | 53 (63.9)       |
| Microadenoma         | 8 (18.2)            |                 |
| Number of resection (n, %) |       |                 |
| 0                    | 8 (17.8)            |                 |
| 1                    | 29 (64.4)           |                 |
| ≥2                   | 8 (17.8)            |                 |
| IGFI (ng/mL)         |                     |                 |
| Before treatment     | 882.5 ± 56          | 234.6 ± 21.3    |
| After treatment      | 100.8 ± 10.4        |                 |
| GH (ng/mL)           |                     |                 |
| Before treatment     | 18.3 ± 2.9          |                 |
| After treatment      | 1.3 ± 0.2           |                 |
| Remission status (n, %) |                   |                 |
| Controlled           | 36 (80)             |                 |
| Uncontrolled         | 9 (20)              |                 |
| Tumor size after treatment (n, %) |        |                 |
| ≥1 cm                | 10 (22.7)           |                 |
| <1 cm                | 34 (77.3)           |                 |
| 25(OH)D3 (nmol/L)    | 5.5 ± 1.1           | 29.9 ± 2.1      |

Data are shown as mean ± standard error. IGFI (% ULN): IGFI/upper limit of normal (age-matched) × 100. *P < 0.001.

### Table 2: Distribution of vitamin D receptor (VDR) genotypes and alleles in acromegaly patients and control subjects.

| TaqI genotypes/alleles | Patients (n, %) | Controls (n, %) |
|------------------------|-----------------|-----------------|
| TT                     | 19 (36.5)       | 38 (45.8)       |
| Tt                     | 29 (55.8)       | 38 (45.8)       |
| tt                     | 4 (7.7)         | 7 (8.4)         |
| T                      | 67 (64.4)       | 114 (68.7)      |
| t                      | 37 (35.6)       | 52 (31.3)       |
| ApaI genotypes/alleles |                  |                 |
| AA                     | 20 (38.5)       | 28 (33.7)       |
| Aa                     | 25 (48.1)       | 43 (51.8)       |
| aa                     | 7 (13.5)        | 12 (14.5)       |
| A                      | 65 (62.5)       | 99 (59.6)       |
| a                      | 39 (37.5)       | 67 (40.4)       |
| FokI genotypes/alleles |                  |                 |
| FF                     | 15 (28.8)       | 29 (34.9)       |
| Ff                     | 32 (61.5)       | 34 (41)         |
| ff                     | 5 (9.6)         | 20 (24.1)       |
| F                      | 62 (59.6)       | 92 (55.4)       |
| f                      | 42 (40.4)       | 74 (44.6)       |

*Frequencies of FokI genotypes between patients and controls (P = 0.034). bFf versus FF + ff (OR: 1.5, 95% CI: 1.07–2.1; P = 0.020). cFf versus FF + Ff (OR: 0.4, 95% CI: 0.16–0.99; P = 0.035).

3. Results

Clinical characteristics of the patients with acromegaly and control group were summarized in Table 1. There was no significant difference in gender and age between patients and healthy subjects (P > 0.05). Genotype distributions for VDR ApaI and TaqI polymorphisms, both in control and patient group, and for FokI polymorphisms in the control group did not deviate significantly from HWE (P > 0.05). However, FokI genotype distributions for the patient group did deviate significantly from HWE (P = 0.04 for patients).

The mean 25(OH)D3 level in acromegaly patients (5.5 ± 1.1 nmol/L) was significantly lower than in controls (29.9 ± 2.1 nmol/L) (P < 0.001). No association was found between 25(OH)D3 levels and any disease characteristics such as tumor size or remission status. Also, 25(OH)D3 levels were not correlated with hormone levels such as GH, IGFI, or IGFI (% ULN). While GH levels before treatment were not correlated with IGFI levels before treatment, GH levels after treatment were correlated with IGFI levels after treatment (P = 0.003, r = 0.44).

We examined three genetic variants of the VDR in acromegaly patients. The distribution of acromegaly patients and controls associated with VDR genotypes is shown in Table 2. There was a significant difference in the frequencies of VDR FokI genotypes between patients and control groups (P = 0.034). VDR FokI ff genotype was significantly decreased in acromegaly patients (9.6%) compared to controls (24.1%) (OR: 0.4, 95% CI: 0.16–0.99; P = 0.035). Carriers of FokI Ff genotype had a 1.5-fold increased risk for acromegaly disease (OR: 1.5, 95% CI: 1.07–2.1; P = 0.020). There was no significant association of either TaqI or ApaI genotypes with acromegaly patients and controls (P > 0.05).

Vitamin D haplotypes (TaqI, FokI, and ApaI) were evaluated for association with acromegaly (data not shown). Haplotype analysis revealed that there was no relationship between VDR haplotypes and acromegaly cases (for acromegaly patients D’ 0.24 LOD: 0.47 r-squared 0.022).

We also analyzed the association of these three polymorphisms with characteristics of acromegaly (Table 3). There was no significant difference in either pretreatment GH levels or serum vitamin D levels across TaqI TT, Tt, and tt genotypes taken as a whole (P > 0.05 for both).

Another finding of this study was the relationship between FokI genotype and hormonal status of acromegaly patients after treatment. We observed that patients with the FF genotype had higher GH levels after treatment.
Table 3: The comparisons of characteristics among the VDR genotypes in acromegaly patients.

| Genotypes | Age onset (years) | GH (ng/mL) | IGF1 (ng/mL) | IGF1 (% ULN) | Tumor size before treatment (cm, %) | Remission (n, %) | 25(OH)D3 (nmol/L) |
|-----------|------------------|------------|-------------|--------------|----------------------------------|-----------------|-------------------|
| Apal      |                  |            |             |              |                                  |                 |                   |
| AA        | 39.5 ± 2.6       | 21.4 ± 5   | 1.15 ± 0.3  | 885.4 ± 78.6 | 248.4 ± 30                      | 321.7 ± 30.6    | 103.5 ± 12.3      |
| Aa        | 40.4 ± 3.2       | 18 ± 4.3   | 1.1 ± 0.2   | 896.4 ± 10.7 | 228 ± 33.2                      | 335.7 ± 33.6    | 101.7 ± 18.4      |
| aa        | 36.1 ± 5.5       | 21 ± 1     | 2.1 ± 1     | 829.6 ± 89.2 | 226.4 ± 59.3                    | 335.4 ± 63.6    | 92.1 ± 18.6       |
| FokI      |                  |            |             |              |                                  |                 |                   |
| FF        | 39.7 ± 3         | 12.5 ± 4.1 | 1.6 ± 0.3   | 907.5 ± 93.1 | 249.5 ± 39.9                    | 344.2 ± 36.8    | 106.8 ± 20.1      |
| Fi        | 39.2 ± 2.6       | 20.7 ± 4.3 | 1.3 ± 0.3   | 869.3 ± 79.6 | 245 ± 29.1³                    | 312.9 ± 27.8    | 104.6 ± 14.2      |
| ff        | 40.2 ± 8.5       | 24.2 ± 8.1 | 0.4 ± 0.1   | 857.3 ± 185.4| 139.6 ± 15.6                   | 377.5 ± 74.8    | 66.3 ± 12.3       |
| TaqI      |                  |            |             |              |                                  |                 |                   |
| TT        | 37.8 ± 3.1       | 11.4 ± 3.1 | 0.8 ± 0.3   | 869.3 ± 108.5| 229.5 ± 25.3                    | 317.5 ± 36.6    | 91.9 ± 9.3        |
| Tt        | 39.6 ± 2.7       | 24.3 ± 4.4 | 1.5 ± 0.3   | 912.7 ± 74.9 | 248.2 ± 3                      | 335.9 ± 28.2    | 110.6 ± 17.8      |
| tt        | 46.5 ± 4.7       | 8.7 ± 3    | 1.97 ± 0.7  | 756.8 ± 14.1 | 149.3 ± 22.3                    | 330.6 ± 75      | 73.3 ± 13.6       |

Data are shown as mean ± standard error. IGF1 (ULN): IGF1/upper limit of normal (age-matched) × 100.

³Ff versus ff P = 0.0049 (Mann-Whitney U test).
than patients with ff genotype, but the difference was only marginally significant \((P = 0.051)\). In addition IGFI levels after treatment were significantly higher in patients carrying the Ff genotype compared to carrying ff genotype \((P = 0.0049)\). No other associations were found between FokI, Apal, or TaqI genotypes and disease characteristics.

4. Discussion

Vitamin D plays a crucial role in a broad variety of hormonal regulations including bone metabolism, immune response, cell proliferation, and differentiation [20]. Many common diseases such as rickets, diabetes, cardiovascular diseases, autoimmune diseases, and cancers have been associated with vitamin D deficiency [21]. Excessive pituitary somatotroph cell proliferation and unrestrained GH hypersecretion are the main pathogenetic events in the course of acromegaly disease development. GH secreting adenomas of anterior pituitary gland which may arise from clonal expansion of somatotroph cells almost always underlie acromegaly disease and this monoclonal origin suggests that intrinsic genetic alterations can play an important role for possible tumorigenic initiating mechanisms [22]. Previous studies indicate that 1,25(OH)2D3, the most active form of vitamin D, regulates the growth and differentiation of various cell types [23]. Moreover, there is growing evidence of regulatory effects on cell death and tumor invasion on tumorigenesis [24]. The VDR gene is one of the most widely studied tumorigenesis-related genes and occurrence of many different types of tumors has been associated with VDR polymorphisms. To our knowledge, this is the first study investigating VDR polymorphisms in acromegaly disease.

In this study we found that, while the VDR FokI ff genotype was associated with a decreased risk, FokI Ff genotype was associated with a significantly increased risk of acromegaly. The FokI polymorphism (thymine/cytosine polymorphism) is the only known VDR gene polymorphism that leads to the generation of an altered protein [25]. The f allele (thymine variant) results in the generation of a longer VDR protein and less transcriptional activity; the F allele results in 1.7-fold more transcriptional activity [26]. Although the majority of the physiological effects of VDR polymorphisms are not fully understood, it has been postulated that these polymorphisms may influence the risk of cancer occurrence [27]. In previous studies VDR polymorphisms have been associated with the risk of breast, prostate, skin, ovary, and bladder carcinoma [28–31] On the other hand, other studies have found no significant association between VDR polymorphisms and cancers [32]. In our study, VDR haplotypes showed no significant difference between patient and control groups. However, it can be noted that FokI polymorphism has not been reported to be in linkage disequilibrium with other VDR polymorphisms and has been considered to be an independent risk marker [33].

In this study, we observed that IGFI levels after treatment were significantly higher in patients carrying Ff genotype compared to these carrying the ff genotype. However, there was no significant difference across FokI genotypes when the IGF levels after treatment were adjusted according to the upper limit of normal IGFI. The VDR TaqI polymorphism is located in a regulatory area rather than in a coding exon and considered to be silent single nucleotide polymorphisms [34]. Although these polymorphisms do not alter the amino acid sequence of the encoded protein, they can affect gene expression through regulation of mRNA stability [35].

Several studies have indicated that acromegaly can be associated with increased 1,25(OH)2D3 levels in treatment naive patients [36]. Consistent with Takamoto et al., we found significantly decreased 25(OH)D3 levels in the patient group without any vitamin D supplement [37]. It is suggested that IGFI stimulation can overactivate renal \(\alpha\)-hydroxylase and increase 1,25(OH)2D3 production [38]. Thereby, decreased 25(OH)D3 level can be an expected finding in acromegaly patients. Along with the evidences of the high occurrence of vertebral fractures despite normal bone mineral density in acromegaly [39], vitamin D status must be considered during follow-up of these patients.

Limitation of the present study was that measurement of exogenous environmental factors effecting vitamin D levels such as UV exposure or daily nutrition containing vitamin D was lacking. Secondly the sample size in the acromegaly group was relatively small due to the rarity of acromegaly and the findings of this study should be demonstrated in larger samples. This study was also a single center based case-control study which could be unrepresentative of acromegaly patients in general population. However, we found similar results compared to previous Turkish studies for the distribution of VDR genotypes [40]. Also it should be noted that our hospital is a reference center admitting patients from all over the country.

In conclusion these findings suggest a possible role of VDR FokI polymorphism in the risk of acromegaly. Vitamin D levels should be considered and followed up in the treatment of acromegaly patients. VDR genotypes can play a role as a consequence of altering hormonal status in the course of acromegaly. Further studies with large numbers are needed to clarify these findings.

Disclosure

The authors have nothing to disclose.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

This study was supported by Bezmialem University Council of Research (6.2012/4).

References

[1] I. M. Holdaway and C. Rajasoorya, “Epidemiology of acromegaly,” Pituitary, vol. 2, no. 1, pp. 29–41, 1999.
S. Melmed, “Acromegaly pathogenesis and treatment,” The Journal of Clinical Investigation, vol. 119, no. 11, pp. 3189–3202, 2009.

A. Beckers and A. F. Daly, “The clinical, pathological, and genetic features of familial isolated pituitary adenomas,” European Journal of Endocrinology, vol. 157, no. 4, pp. 371–382, 2007.

L. Vallar, A. Spada, and G. Giannattasio, “Altered Gs and adenylyl cyclase activity in human GH-secreting pituitary adenomas,” Nature, vol. 330, no. 6148, pp. 566–568, 1987.

L. Pei and S. Melmed, “Isolation and characterization of a pituitary tumor-transforming gene (PTTG),” Molecular Endocrinology, vol. 11, no. 4, pp. 433–441, 1997.

J. Bertherat, P. Chanson, and M. Montminy, “The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas,” Molecular Endocrinology, vol. 9, no. 7, pp. 777–783, 1995.

E. Giovannucci, “The epidemiology of vitamin D and cancer incidence and mortality: a review (United States),” Cancer Causes & Control, vol. 16, no. 2, pp. 83–95, 2005.

M. Liu, M.-H. Lee, M. Cohen, M. Bomnakanti, and L. P. Freedman, “Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937,” Genes & Development, vol. 10, no. 2, pp. 142–153, 1996.

M. Labuda, T. M. Fujitawara, M. V. Ross et al., “Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13-14,” Journal of Bone and Mineral Research, vol. 7, no. 12, pp. 1447–1453, 1992.

M. R. Haussler, C. A. Haussler, P. W. Jurutka et al., “The vitamin D hormone and its nuclear receptor: molecular actions and disease states,” The Journal of Endocrinology, vol. 154, pp. S57–S73, 1997.

J. Guiubourdencbe, C. Dijakouere, D. Porquet et al., “Retinoic acid stimulates growth hormone synthesis in human somatotrop adenomas: characterization of its nuclear receptors,” Journal of Cellular Biochemistry, vol. 65, no. 1, pp. 25–31, 1997.

M. L. Slattery, “Vitamin D receptor gene (VDR) associations with cancer,” Nutrition Reviews, vol. 65, supplement 2, pp. S102–S104, 2007.

C. D. Davis, “Vitamin D and cancer: current dilemmas and future research needs,” The American Journal of Clinical Nutrition, vol. 88, no. 2, pp. 5655–5695, 2008.

Q. Chen and A. C. Ross, “Vitamin A and immune function: retinoic acid modulates population dynamics in antigen receptor and CD38-stimulated splenic B cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 40, pp. 14142–14149, 2005.

A. Giustina, P. Chanson, M. D. Bronstein et al., “A consensus on criteria for cure of acromegaly,” The Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 7, pp. 3141–3148, 2010.

S. A. Miller, D. D. Dykes, and H. F. Polesky, “A simple salting out procedure for extracting DNA from human nucleated cells,” Nucleic Acids Research, vol. 16, no. 3, article 1215, 1988.

I. Yaylim-Eraltan, H. A. Ergen, S. Arikan et al., “Investigation of the VDR gene polymorphisms association with susceptibility to colorectal cancer,” Cell Biochemistry and Function, vol. 25, no. 6, pp. 731–737, 2007.

T. Carling, P. Ridefelt, P. Hellman, J. Rastad, and G. Åkerström, “Vitamin D receptor polymorphisms correlate to parathyroid cell function in primary hyperparathyroidism,” The Journal of Clinical Endocrinology & Metabolism, vol. 82, no. 6, pp. 1772–1775, 1997.

J. C. Barrett, B. Fry, J. Maller, and M. J. Daly, “Haplotype analysis and visualization of LD and haplotype maps,” Bioinformatics, vol. 21, no. 2, pp. 263–265, 2005.

M. R. Haussler, G. K. Whitfield, C. A. Haussler et al., “The nuclear vitamin D receptor: biological and molecular regulatory properties revealed,” Journal of Bone and Mineral Research, vol. 13, no. 3, pp. 325–349, 1998.

A. G. Uitterlinden, Y. Fang, J. B. J. van Meurs, H. A. P. Pols, and J. P. T. M. Van Leeuwen, “Genetics and biology of vitamin D receptor polymorphisms,” Gene, vol. 338, no. 2, pp. 143–156, 2004.

V. Herman, J. Fagan, R. Gonsky, K. Kovacs, and S. Melmed, “Clonal origin of pituitary adenomas,” The Journal of Clinical Endocrinology and Metabolism, vol. 71, no. 6, pp. 1427–1433, 1990.

R. J. Frampton, S. A. Omdad, and J. A. Eisman, “Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites,” Cancer Research, vol. 43, no. 9, pp. 4443–4447, 1983.

P. Ordonez-Moran, M. J. Larribia, N. Pendas-Franco, O. Aguilara, J. M. Gonzalez-Sancho, and A. Munoz, “Vitamin D and cancer: an update of in vitro and in vivo data,” Frontiers in Bioscience, vol. 10, no. 2, pp. 2723–2749, 2005.

H. Arai, K.-I. Miyamoto, Y. Taketani et al., “A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women,” Journal of Bone and Mineral Research, vol. 12, no. 6, pp. 915–921, 1997.

P. W. Jurutka, L. S. Remus, G. K. Whitfield et al., “The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIb,” Molecular Endocrinology, vol. 14, no. 3, pp. 401–420, 2000.

R. D. Mittal, P. K. Manchanda, S. Bhat, and H. K. Bid, “Association of vitamin-D receptor (Fok-I) gene polymorphism with bladder cancer in an Indian population,” BJU International, vol. 99, no. 4, pp. 933–937, 2007.

G. Lurie, L. R. Wilkens, P. J. Thompson et al., “Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk,” Cancer Epidemiology Biomarkers & Prevention, vol. 14, no. 10, pp. 2335–2339, 2005.
[33] J. M. Zmuda, J. A. Cauley, and R. E. Ferrell, “Molecular epidemiology of vitamin D receptor gene variants,” Epidemiologic Reviews, vol. 22, no. 2, pp. 203–217, 2000.

[34] Y. Fang, J. B. J. van Meurs, A. D’Alesio et al., “Promoter and 3’-untranslated-region haplotypes in the vitamin D receptor gene predispose to osteoporotic fracture: the Rotterdam study,” The American Journal of Human Genetics, vol. 77, no. 5, pp. 807–823, 2005.

[35] P. W. Jurutka, G. K. Whitfield, J.-C. Hsieh, P. D. Thompson, C. A. Haussler, and M. R. Haussler, “Molecular nature of the vitamin D receptor and its role in regulation of gene expression,” Reviews in Endocrine and Metabolic Disorders, vol. 2, no. 2, pp. 203–216, 2001.

[36] P. Kamenický, A. Blanchard, C. Gauci et al., “Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria?” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 6, pp. 2124–2133, 2012.

[37] S. Takamoto, H. Tsuchiya, T. Onishi et al., “Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy,” The Journal of Clinical Endocrinology & Metabolism, vol. 61, no. 1, pp. 7–11, 1985.

[38] C. Menaa, F. Vrtovsnik, G. Friedlander, M. Corvol, and M. Garabédian, “Insulin-like growth factor I, a unique calcium-dependent stimulator of 1,25-dihydroxyvitamin D3 production: studies in cultured mouse kidney cells,” Journal of Biological Chemistry, vol. 270, no. 43, pp. 25461–25467, 1995.

[39] M. J. E. Wassenaar, N. R. Biermasz, N. A. T. Hamdy et al., “High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly,” European Journal of Endocrinology, vol. 164, no. 4, pp. 475–483, 2011.

[40] D. Dayangac-Erden, A. Karaduman, and H. Erdem-Yurter, “Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients,” Archives of Dermatological Research, vol. 299, no. 10, pp. 487–491, 2007.